TOV-2295 (R) cell line
- Name Anne-Marie Mes-Masson and Diane Provencher
- Institute Centre Hospitalier de Luniversité de Montréal
- Primary citation Létourneau et al. 2012. BMC Cancer. (12): 379. PMID: 22931248
Tool name: TOV-2295 (R) cell line
Alternate names: TOV-2295 (R)
Tool type: Cell Lines
Donor: Grade 3 Stage IIIC; Mutations: TP53 Exon 6; Cisplatin/Topotecan &; Paclitaxel/Carboplatin/Doxorubicin
Tissue: Derived from solid tumor of patient diagnosed with high-grade serous ovarian cancer at specific time points at diagnosis and relapse
Cancer type: Gynaecologic cancer
Morphology: Aquired resistance to carboplatin.
Expresssion of tumor suppressor p53 present.
Strong HER2 expression detected in protein extracts and observed in solid tissues by IHC.
Spheroid formation: aggregate
Growth properties: Adherent
Receptors of note: No
Description: Epithelial ovarian cancer cell lines spontaneously derived from solid tumor at specific time points at diagnosis and relapse. Primary treatment was a combination of cisplatin/topotecan and later treatment included carboplatin, paclitaxel, and doxorubicin
Research area: Cancer
Production details: Established using the Scrape method where tumor tissue was scraped into a 100mm plate with complete OSE medium and maintained for 40 days with medium replaced weekly.
Additional notes: Patient 2295 was diagnosed with ovarian cancer following imaging, ascites puncture, and partial ommentectomy. Patient was included in a clinical trial and treated with cisplatin/topotecan for the first four months following diagnosis. From months 4-7, patient received carboplatin and paclitaxel and responded well to chemotherapy initially. Three months after the end of chemotherapy however, ascites volume increased and later underwent ovarian cytoreduction. Eleven months after diagnosis, she receieved low doses of doxorubicin which she did not respond.
- For Research Use Only
- • Tomas et al. 2023. J Ovarian Res. 11
- • 16(1):70. PMID: 37038202
Vias et al. 2023. Elife. 11
- • 12:e83867. PMID: 37166279
Jubelin et al. 2022. Cell Biosci. 11
- • 12(1):155. PMID: 36089610
Canals et al. 2022. Front Oncol. 4
- • 12:856424. PMID: 35600398